TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2000035
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg body weight (BW) protein meal
Study: 2000035
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg BW protein meal
Study: 2000035
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg BW protein meal
Study: 2000035
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg BW protein meal
Study: 2000035
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg BW protein meal
Study: 27111273
Drug: Partially hydrolysed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF‐OS)
Study: 18062596
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (prolonged conservative treatment with later surgery if necessary)
Study: 16130059
Drug: Ketamine anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine anesthesia (IV ketamine 1 to 2 mg/kg, fentanyl 1 to 2 microg/kg, maintained with ketamine 25 to 75 microg/kg/min and fentanyl 10 microg/kg/h)
Study: 16130059
Drug: Isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anesthesia (IV thiopental sodium 3 to 5 mg/kg, fentanyl 1 to 2 microg/kg, maintained with 1% isoflurane and fentanyl 10 microg/kg/h)
Study: 8757425
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 1,000 mg alone
Study: 8757425
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 500 mg + low-dose interferon-alpha (IFN-alpha 3 MIU three times weekly)
Study: 30703349
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) and education only
Study: 30703349
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection plus physical therapy (ESI+PT)
Study: 26460229
Drug: 24-weeks group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-weeks group (discontinuation of risperidone or olanzapine at 24 weeks)
Study: 24436491
Drug: Renal-specific oral
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal-specific oral nutrition supplement (RS-ONS)
Study: 22952598
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 8 g/d (1.6 g/d EPA+DHA)
Study: 22952598
Drug: High oleic
Normalized name: High Oleic Sunflower Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleic sunflower oil (HOSO) 8 g/d
Study: 19544043
Drug: Splinting plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splinting plus low-level laser therapy (SLLLT)
Study: 17894323
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of ribavirin (RBV)
Study: 17894323
Drug: Flat dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat dosing of ribavirin (RBV)
Study: 11132612
Drug: Sildenafil (25-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25-200 mg)
Study: 9113185
Drug: ALAGLN-group (alanyl-glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALAGLN-group (alanyl-glutamine solution)
Study: 9113185
Drug: AA-group (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-group (glucose and balanced amino acid solution)
Study: 9493699
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg
Study: 9493699
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg
Study: 27474536
Drug: Single solar‐simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single solar‐simulated UVR exposure of 3 Standard Erythema Dose at 30 minutes or 24 hours after IPL
Study: 21988742
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (200 U/kg intravenously)
Study: 16503705
Drug: Stepwise methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise methadone induction (28, 56, then 84 mg/day)
Study: 16503705
Drug: Rapid methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid methadone induction (28-84 mg on Days 1-6 to 56 mg/day)
Study: 12905979
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (PPI + bismuth-based triple therapy)
Study: 12905979
Drug: PPI-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based triple therapy
Study: 3920861
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Sorbinil
Study: 3920064
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Sorbinil
Study: 3920064
Drug: Topical 0.5
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5 mg ophthalmic Sorbinil
Study: 3920064
Drug: Oral Sorbinil
Normalized name: sorbitol Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Sorbinil
Study: 3920064
Drug: Topical ophthalmic
Normalized name: MIOTICS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic preparation
Study: 20617660
Drug: Voluntary management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary management breathing control therapy
Study: 10632415
Drug: Transdermal 17beta‐E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐E2 (50 microg/d)
Study: 10632415
Drug: Transdermal 17beta‐E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐E2 (50 microg/d) + norethisterone acetate (250 microg/d)
Study: 8795747
Drug: Glaucoma treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucoma treatment interventions (specifics not provided)
Study: 8795747
Drug: Controlled trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled trials of glaucoma treatments (specifics not provided)
Study: 26603250
Drug: Cognitive‐behavioural therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural therapy (CBT)
Study: 18234488
Drug: 800 mg/d
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/d of imatinib (400mg BID)
Study: 18234488
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d of imatinib
Study: 10100554
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) 3 g/m2
Study: 10100554
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CY) 4 g/m2
Study: 10100554
Drug: Prior chemotherapy
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior chemotherapy regimen (1 regimen)
Study: 10100554
Drug: Prior chemotherapy
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior chemotherapy regimen (>=2 regimens)
Study: 8947399
Drug: Hamstring tendons-ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamstring tendons-ligament augmentation device anterior cruciate ligament reconstructions
Study: 1768562
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of indocyanine green (ICG) at 1.0 mg min‐1 for 150 min
Study: 1768562
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (10 mg in 10 min)
Study: 1768562
Drug: Three 1-min
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 1-min infusions of ICG (0.5 mg kg‐1) administered at corresponding times of the day
Study: 27605086
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of beta-carotene and vitamin C supplements
Study: 25908099
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg by intravenous bolus injection
Study: 19176949
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic lock solution of gentamicin (4 mg/ml) heparin (G group)
Study: 19176949
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (H group)
Study: 11493411
Drug: Atovaquone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (1,000 mg) and proguanil hydrochloride (400 mg) daily for 3 days
Study: 11493411
Drug: Chloroquine (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (1,500 mg over 3 days)
Study: 11493411
Drug: Pyrimethamine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (75 mg) and sulfadoxine (1,500 mg) as a single dose
Study: 9715425
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg) plus amoxycillin (500 mg) twice daily for 2 weeks (LA-60 group)
Study: 9715425
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily) plus amoxycillin (500 mg twice daily for 2 weeks (LA-30 group)
Study: 9715425
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily for 6 or 8 weeks (LPZ group)
Study: 2375945
Drug: Caffeine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine, 10 mg/kg
Study: 385096
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (500 mg b.d.) for 7 days before operation
Study: 31915996
Drug: Enoxaparin-warfarin (enox-warfarin)
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin-warfarin (enox-warfarin)
Study: 25819354
Drug: ossein-hydroxyapatite complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ossein-hydroxyapatite complex (OHC) 1,660 mg/day
Study: 25819354
Drug: calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium carbonate (CC) 1,200 mg/day
Study: 25819354
Drug: calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium carbonate (CC)
Study: 24786946
Drug: Build Better
Approvals — FDA: no, EMA: no, PMDA: no
Description: Build Better Bones With Exercise (B3E) intervention including exercise and behavioral counseling, delivered by a physical therapist in 6 home visits over 8 months, and monthly calls; participants are to exercise ≥3 times weekly.
Study: 8600188
Drug: Sorbitol gum
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol gum (9.0 g/day)
Study: 2469708
Drug: cetirizine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine, 20 mg
Study: 1096218
Drug: Haloperidol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (9 mg/day)
Study: 1096218
Drug: Clozapine (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (225 mg/day)
Study: 26303014
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course concurrent palliative chemotherapy (cisplatin at 6mg/m2/day IV bolus for 5 days) plus radiotherapy (RT as arm A)
Study: 21504334
Drug: Sitagliptin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin administration alone or with a concomitant drug
Study: 8186781
Drug: Intravenous alfentanil-midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil-midazolam anesthesia
Study: 2660754
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 gr. IM daily for 7 days)
Study: 30953731
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (waitlist control)
Study: 19749496
Drug: Other statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other statins (Simvastatin 40 mg/day, Pravastatin 40 mg/day)
Study: 16802360
Drug: Calcium (1,000
Normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,000 mg) and vitamin D (400 IU) supplementation
Study: 9305226
Drug: Antihistamine-treated group
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-treated group
Study: 9305226
Drug: Immunotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy group
Study: 29307660
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 μg/day for 12 weeks)
Study: 29092731
Drug: Single CER
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single CER intact capsule (30 mg)
Study: 29092731
Drug: Single CER
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single CER capsule contents sprinkled over applesauce (15 mL)
Study: 24136051
Drug: Zero-profile implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zero-profile implant
Study: 19100931
Drug: Rocuronium (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.3 mg kg(‐1) IV)
Study: 19100931
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg kg(‐1) IV)
Study: 16785771
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy (PCT)
Study: 20621334
Drug: Cognitive‐behavior therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavior therapy (CBT)
Study: 12695418
Drug: NG‐monomethyl‐L‐arginine (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (nitric oxide synthase inhibitor)
Study: 1514723
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulfate (3 mL, 268 mmol/L, pH 6.4)
Study: 1514723
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (2.5 mg in 3 mL saline)
Study: 1514723
Drug: Nebulized normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized normal saline (3 mL)
Study: 26720847
Drug: 70 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 IU/kg intravenous unfractionated heparin (UFH) bolus
Study: 11865170
Drug: Prednisolone 10
Normalized name: prednisolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 10 mg tid
Study: 11865170
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (less severe hyperemesis, no steroid therapy)
Study: 10199874
Drug: L-arginine (6.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6.7 g/min for 45 minutes)
Study: 10199874
Drug: DIP (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIP (intravenous dipyridamole)
Study: 8786246
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (150 mg twice daily) - Neoral
Study: 8786246
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (150 mg twice daily) - Sandimmune
Study: 6996935
Drug: guanabenz (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanabenz (mean dose 24 mg daily)
Study: 31419023
Drug: Structured ostomy
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured ostomy care training (oral and practical training, question and answer session, and an ostomy information booklet)
Study: 12750665
Drug: 1-phase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-phase treatment with bionator
Study: 19577150
Drug: 2-phase treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-phase treatment with headgear/biteplane
Study: 18046226
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of high-dose triamcinolone acetonide (20-25 mg)
Study: 18046226
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of dexamethasone (500 mug)
Study: 15501952
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 i.v. day 1) and capecitabine (1000 mg/m2 orally twice daily days 2‐15) for four cycles (Dose A)
Study: 15501952
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 i.v. day 1) and capecitabine (937.5 mg/m2 orally twice daily days 2‐15) for four cycles (Dose B)
Study: 11384089
Drug: Capecitabine as
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine as first-line treatment for metastatic breast cancer
Study: 11384089
Drug: Low-dose CMF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CMF (control group)
Study: 9021428
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (450 mg propafenone)
Study: 9021428
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (600 mg propafenone)
Study: 3148366
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered thyrotropin-releasing hormone (TRH) (40 mg/day for 10 days)
Study: 29685026
Drug: Biophysical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biophysical therapy using a Med Select 729 device
Study: 29685026
Drug: Ibuprofen (non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (non-steroidal anti-inflammatory drug)
Study: 25234648
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa at 2.0 mg/kg administered weekly for 24 weeks
Study: 25234648
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa at 2.0 mg/kg administered every other week for 24 weeks
Study: 25234648
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing cohort
Study: 25234648
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing cohorts
Study: 23261008
Drug: PSYMEPHY (interdisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSYMEPHY (interdisciplinary treatment, 12 sessions)
Study: 23261008
Drug: Standard pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacologic therapy (control group)
Study: 18690162
Drug: tesamorelin 2
Normalized name: tesamorelin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesamorelin 2 mg
Study: 10746426
Drug: Alendronate 35
Normalized name: ALENDRONATE 35MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 35 mg twice-weekly
Study: 10746426
Drug: Once-weekly dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly dosing group
Study: 8636828
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (1500 micrograms of beclomethasone via spacer for 30 days)
Study: 8636828
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without inhaled corticosteroids
Study: 4054524
Drug: Polycose meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycose meal volume of 300 ml
Study: 4054524
Drug: Polycose meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycose meal energy density of 0.7 kcal/ml
Study: 31895638
Drug: Unpreserved 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpreserved 0.9% saline solution (Hydrabak®) eye drops
Study: 29976109
Drug: Theoretical narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theoretical narrative medicine education for 1 term (Group 2)
Study: 29976109
Drug: Narrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative medicine education integrating theory with practice for 2 terms (Group 3)
Study: 27515419
Drug: cilnidipine (N/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilnidipine (N/L type CCB)
Study: 27515419
Drug: amlodipine (L
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (L type CCB)
Study: 24573731
Drug: L-menthol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol (20 mL of 1.6% L-menthol)
Study: 15829018
Drug: Zafirlukast (leucotriene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (leucotriene antagonist) for four weeks, along with doxycycline
Study: 12005317
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 to 15 mg)
Study: 11199824
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment at cervical regions with black ink
Study: 11199824
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment at cervical regions without black ink
Study: 11199824
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment at apical regions with black ink
Study: 11199824
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment at apical regions without black ink
Study: 8705220
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin twice daily for one week
Study: 8705220
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin twice daily for one day
Study: 8705220
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin twice daily for one week (in patients with risk factors)